HRT Black Box Warning Removed:
What Women Need to Know
What Happened?
The FDA recently removed the black box warning from most Hormone Replacement Therapy (HRT) products. This warning, introduced in 2003 after the Women’s Health Initiative (WHI) study, highlighted risks like breast cancer and heart disease.
The FDA says new evidence shows HRT can be safe and beneficial for women under 60 or within 10 years of menopause.
Why the Concern?
Critics argue the decision skipped a formal advisory committee and lacked transparent, rigorous review. Safety labels exist for a reason. They guide informed choices. Removing them without due process risks oversimplifying complex science.
Benefits vs Risks
Potential benefits: Reduced heart attacks, bone fractures and cognitive decline for younger menopausal women.
Risks remain: Slight increase in breast cancer risk for some, especially with systemic estrogen.
Why This Matters for Black & Marginalised Women
Earlier menopause onset and more severe symptoms.
Lower access to HRT: Black women are up to 5× less likely to receive HRT than white women.
Cultural and systemic barriers: Distrust, lack of tailored advice, and underrepresentation in clinical trials.
Equity gap: Without clear safety guidance, these communities' risk being left behind in informed care.
Your Voice Matters
Have you faced challenges accessing menopause care or HRT?
By the FDA removing the HRT black box warning what does this mean for Black and marginalised women?
Share your experience with us. Your insights will help shape future conversations and resources for women like us.
